Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
The Complexity of the Pharma Supply Chain
The pharmaceutical supply chain is a globally dispersed network dominated by China and India, where most active pharmaceutical ingredients (APIs) are produced. Stringent regulations such as the FDA’s Drug Supply Chain Security Act (DSCSA) demand full batch traceability, limiting rapid supplier changes. About 70% of top‑selling drugs rely on costly cold‑chain logistics, with temperature failures causing roughly $35 billion in annual losses. Emerging threats—including geopolitical tensions, supply‑side concentration, and cyberattacks—are prompting reshoring and diversification strategies.
Building an AI-Driven 'ChatGPT of Human DNA'
Mount Sinai, the ARC Innovation Center, and Nvidia have announced a joint effort to develop AI models capable of decoding the human genome. Leveraging Nvidia’s GPU platforms and large‑scale machine‑learning frameworks, the partnership will create tools that translate raw DNA...
Job Market Slips as Medicaid Work Rules Tighten
The job market is weakening as work requirements are poised to go into effect for Medicaid and ACA premium assistance is decreasing.
Privacy Expectations in Consumer AI Tools: How Patient Use of ChatGPT Health and Claude Differs From HIPAA-Regulated Care
OpenAI and Anthropic are rolling out both enterprise‑grade AI suites for hospitals and consumer‑focused health assistants like ChatGPT Health and Claude Pro. Enterprise tools operate under HIPAA, allowing covered entities to negotiate Business Associate Agreements that impose strict data safeguards....
Pilots to Production: Taiwan’s Practical AI for Systems Under Strain
U.S. hospitals are grappling with staffing shortages, rising patient volumes, and a proliferation of AI pilots that never scale. At HIMSS 2026, Taiwan’s Excellence Pavilion showcased a suite of deployment‑ready, interoperable AI solutions designed to integrate instantly into clinical workflows....
CMS Plans Advance Care Planning Quality Measure
The U.S. Centers for Medicare & Medicaid Services has proposed a new advance care planning (ACP) quality measure, MUC202-020, that would tie reimbursement to documented end‑of‑life conversations for patients 18 and older. The measure would apply to hospitals, home health...
The Advent of Vibe Coding in Healthcare: Orchestrating the Future of Medical Software Development
Vibe coding, introduced by Andrej Karpathy in early 2025, replaces traditional syntax‑heavy programming with natural‑language driven AI agents that can generate, debug, and deploy healthcare applications. The approach empowers clinicians to act as developers, dramatically lowering the cost and time...
Check Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers
The article outlines the legal requirement that U.S. wholesale drug distributors and third‑party logistics providers (3PLs) must hold a valid state license to handle prescription medications. It warns that unlicensed or unauthorized partners can expose patients to counterfeit, stolen, or...
Staying Cyber Alert and Cyber Ready
The American Hospital Association (AHA) is coordinating with the FBI and other federal agencies to monitor cyber threats amid heightened geopolitical tensions, including the Iran conflict. While no specific threats to U.S. health care have been confirmed, the AHA urges...
Elation Health Launches AI Fast Lane to Automate Primary Care Billing Workflows
Elation Health has introduced an AI‑driven billing engine that creates a touchless fast lane for primary‑care claims. The system pulls context from the Elation EHR—pre‑visit data, AI‑drafted notes, problem lists and medications—to suggest complete diagnosis, procedure and drug codes before...
J&J Wins Third National Priority Approval for Multiple Myeloma Combo
Johnson & Johnson’s Tecvayli and Darzalex combination received FDA approval for second‑line multiple myeloma treatment, marking the third drug cleared under the Commissioner’s National Priority Voucher (CNPV) program. The decision was rendered in just 55 days after J&J’s filing, thanks...
The Dozortsev-Diamond Paradigm: Is Progesterone the True Ovulation Trigger?
A new ovulation model from Dmitri Dozortsev and Michael Diamond argues that a modest rise in progesterone, not estradiol, triggers the LH surge that leads to ovulation. The paradigm links follicle size‑induced cortical disruption to a switch from estradiol to...
Go for Bold: Improving Outcomes One Pound at a Time
Meritus Health launched the Go for Bold campaign in 2020, aiming to shed 1 million lb across Washington County, Maryland by 2030. By December 2024 the initiative recorded more than 160,000 lb lost among 7,700 participants, supported by 55 community partners. The program’s three‑pillared...
Mayo Clinic Platform_Accelerate Announces Latest Cohort of 18 Digital Health Companies
Mayo Clinic Platform Accelerate has announced a new 30‑week cohort of 18 digital‑health startups from across the globe. Participants will receive mentorship from Mayo clinicians and, crucially, access to millions of de‑identified longitudinal clinical records to train and validate AI models....
Epic Partnerships Shrink, Garden Plot Expansion Leads 2026
@HeyEpic's Workshop category is down to 3 vendors, as @PressGaney just got moved to Toolbox, and the rest are likely to follow. So what does it actually look like to partner with Epic in 2026? I mapped it out (from...
Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection
The FDA has issued a draft Level 1 guidance (Docket FDA‑2025‑D‑1504) titled “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” The document targets both foreign and domestic manufacturers of human and animal drugs regulated by CDER,...
Women’s Brain Health—And Companies—Get A Boost Long-Term
Emerging studies reveal that motherhood and menopause can act as neuroprotective milestones, strengthening women’s cognitive reserve and even thickening grey‑matter regions linked to memory. Researchers at Monash University found older mothers exhibit younger brain‑activity patterns, while Dr. Lisa Mosconi reports...
From MFN to IRA, Experts Warn of a System Under Pressure in Wide-Ranging Policy Webinar
The March 3, 2026 AJMC/MHE webinar examined the Trump administration’s Great Healthcare Plan, focusing on most‑favored‑nation (MFN) drug pricing, the lapse of ACA marketplace subsidies, and the Inflation Reduction Act’s (IRA) impact on community oncology. Sixteen manufacturers have voluntarily adopted MFN pricing,...
Stem Cells Show Promise for Neurodegenerative Disease Treatment
A narrative review on the therapeutic potential of stem cells in neurodegenerative diseases: advances, insights, and challenges 👉"Stem cell therapy offers regenerative potential for neurodegenerative diseases. 👉Mesenchymal stem cells (MSCs), induced pluripotent stem cells, and neural stem cells show promise through neuroprotection...
Biopharma’s Recent String of CEO Splits
Three biopharma firms—Bavarian Nordic, Sarepta Therapeutics, and Alkermes—announced the departures of long‑standing CEOs, prompting short‑term share declines. Bavarian Nordic’s Paul Chaplin steps down after a blocked $3 billion buyout, while Sarepta’s Doug Ingram leaves amid family health issues and recent product...
BBC Infographic Explains UniQure Gene Therapy for Huntington
Especially after the recent disappointing regulatory update regarding $QURE AMT-130 clinical candidate for treating Huntington disease and the FDA refusal to move forward 🧵👇- here is an excellent Infograph by the BBC which explains how exactly the mechanism of @uniQure_NV’s...
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Immuneering Corporation announced its 2025 financial results, highlighting a 64% overall survival rate at 12 months for atebimetinib plus modified gemcitabine/nab‑paclitaxel in first‑line pancreatic cancer. The company secured FDA and EMA alignment on the design of its pivotal Phase 3 MAPKeeper 301...
Lancet Study Validates Digital Stethoscopes for Primary Care
In early 2026, The Lancet published the TRICORDER study, a pragmatic, real-world evaluation involving 205 primary care practices and about 1.5 million patients, proving that digital stethoscopes have a place in care. For clinicians seeking practice-ready digital transformation, this device could...
Servier's $2.5B DAWN Deal Closes Ojemda Saga
$DAWN acquisition by Servier for $2.5bn is quite the ending for Ojemda. Who remembers this RAF inhibitor's bizarre & convoluted history? $BIIB $TAK https://t.co/uD5drO9ymr
Friday Radio Prep
The post notes three breaking headlines: the United States has launched military operations in Ecuador, Senate Republicans have blocked a resolution on Iran war powers, and there are rumors of a potential repo involving CNN. The Ecuador mission is framed...
Proanthocyanidins Show Promising Neuroprotective Mechanisms
Advance in neuroprotective effects of proanthocyanidins (PCs): Structure, absorption, bioactivities, mechanism, and perspectives https://t.co/AMfxcjo4m6 https://t.co/oTMCLW0CKL
Republican Budget Threatens Social Security and Medicare Solvency
Republican lawmakers passed a federal budget that slashes Medicare and Medicaid spending by up to $1 trillion over the next decade. The Congressional Budget Office estimates the cuts cut 12 years off Medicare Part A’s projected solvency and will push Social Security’s...
Administrative Workforce Stability: The New Clinical Metric for 2026
In 2025, health‑care providers grappled with chronic administrative staffing shortages that slowed billing, disrupted scheduling, and ate into clinicians' patient time. By 2026, industry leaders are converting workforce stability into a formal clinical metric, tracking turnover, fill‑time and continuity for...
Magnetic Nanoparticles Could Make Doxorubicin Delivery More Precise
Researchers have engineered a magnetic nanocarrier (IO@MBD) that combines γ‑Fe₂O₃ nanoparticles with a melamine‑based dendrimer to deliver doxorubicin. The platform achieves roughly 17 wt% drug loading, remains dispersible in water, and releases the drug preferentially under acidic conditions typical of tumor...
Blood-Based Metabolomics May Enable Earlier Detection of Gallbladder Cancer, Study Finds
Researchers from Tezpur University and the University of Illinois Urbana‑Champaign identified blood‑based metabolic signatures that distinguish gallbladder cancer patients—both with and without gallstones—from individuals with gallstones alone. Using untargeted metabolomics, they detected 180 to 225 altered metabolites, many linked to...
From Approval to Access: 4 Steps to Rethinking Market Access Strategy in Specialty Pharma
The article outlines a four‑step framework for specialty pharma companies to redesign market‑access strategies as they move from approval to commercial launch. It stresses securing payer formulary placement, deploying a focused sales force, establishing a trusted pharmacy network, and centering...
Pharma Pulse: Eli Lilly’s Employer Connect Platform and Tandem Mobi Android Integration
Eli Lilly has introduced Employer Connect, a new platform that partners with more than fifteen independent administrators to provide cost‑transparent access to its obesity drug Zepbound for U.S. employees. The service is designed to close the insurance coverage gap affecting roughly...
Johnson & Johnson Reports the US FDA Approval of Tecvayli + Darzalex Faspro for R/R Multiple Myeloma
Johnson & Johnson announced FDA approval of the Tecvayli (teclistamab) and Darzalex Faspro (subcutaneous daratumumab with hyaluronidase) combination for adults with relapsed/refractory multiple myeloma who have received at least one prior line of therapy. The approval is grounded in the Phase III...
Seqster Unveils 1-Click DataLake for Clinical Trials
Seqster has introduced 1‑Click DataLake, a real‑world data platform that aggregates anonymized electronic health‑record information from over 150 million patients and 200,000 clinicians across the United States. The solution delivers real‑time, longitudinal patient journeys to speed trial design, feasibility assessments, and...
Liberate Bio Gains Licences for Myeloid-Specific CAR Design Patents
Liberate Bio announced it has secured both exclusive and non‑exclusive licenses for patents covering chimeric antigen receptor (CAR) designs specifically engineered for myeloid cells such as monocytes and macrophages. The patents, obtained from Carisma Therapeutics and the University of Pennsylvania,...
RethinkBH Launches Session Note AI for ABA Clinicians
Rethink Behavioral Health unveiled Session Note AI, an artificial‑intelligence driven documentation tool for applied behavior analysis (ABA) clinicians. The solution creates structured session summaries directly from real‑time session data, cutting manual entry and ensuring compliance with payer standards. It promises...
How the ‘Holy Grail’ Weight Loss Pill Became a Reality, and What Comes Next
The pharmaceutical industry has finally delivered an oral GLP‑1 weight‑loss pill, with Novo Nordisk launching an oral version of Wegovy earlier this year. Eli Lilly’s oral GLP‑1 candidate, orforglipron, is expected to receive approval imminently. Oral formulations overcome the injection barrier that...
Digital Health and Care Wales Seeks £5 Million Intelligent Audit Solution
Digital Health and Care Wales (DHCW) has launched a £4.9 million procurement for a National Intelligent Integrated Audit Solution to monitor user access across the NHS Wales single patient record, clinical applications and data repositories. The cloud‑based platform must ingest audit...
Reversing Tumor Immunosuppression with Next-Gen GPCR Modulation
Kainova Therapeutics, formerly Domain Therapeutics, announced a Series B funding round to advance its next‑generation GPCR‑modulating platform aimed at reversing tumor immunosuppression. The rebrand signals a strategic shift toward a broader oncology focus, leveraging GPCR pathways that control immune cell trafficking....
LexisNexis Brings Deepfake and Fraud Defense to Epic MyChart
LexisNexis Risk Solutions is expanding its identity‑verification suite within Epic’s Connection Hub, enabling U.S. hospitals to embed advanced security tools directly into MyChart. The integration adds AI‑driven behavioral analytics, OTP authenticators, and other modular components to protect patient health data...
Harrison.ai Secures the US FDA 510(k) Clearance for Acute Infarct Triage on Non-Contrast CT Brain
Harrison.ai has received U.S. FDA 510(k) clearance for its Acute Infarct Triage software, which analyzes non‑contrast CT brain scans to identify acute ischemic strokes. In validation studies the algorithm achieved roughly 89% sensitivity on thin‑slice CT and 86% on thicker...
Overcoming Thermal Latency: A Passive Architecture for High-Flux Imaging
Medical imaging systems such as MRI and CT are hitting a thermal latency gap where millisecond‑scale heat spikes outpace conventional liquid cooling loops. SkySpigot proposes a passive vacuum‑sorption architecture that captures these spikes using a rapid flash‑absorption phase change and...
Ensuring Fatigue Resistance of Polymer Welds for Medical Devices
Polymer welds are integral to medical devices, yet their fatigue resistance often goes untested. EWI’s recent study showed that under‑welded joints, which lack intermolecular diffusion, appear flawless but fail quickly under cyclic loading. Using Heated After Cross‑Section (HACS) analysis, the...
This Week in European MedTech and HealthTech: 6th March 2026
The European Commission unveiled a Health Package that revises the MDR/IVDR, removes the five‑year certificate cap and introduces risk‑based surveillance, while hard‑wiring cybersecurity reporting and aligning high‑risk AI obligations with the AI Act. The package also launches the first phase...
Roche and Zealand Pharma Report P-II (ZUPREME-1) Trial Data on Petrelintide in Obesity
Roche and Zealand Pharma disclosed Phase‑II (ZUPREME‑1) results for petrelintide, an amylin‑analog injected weekly, in 493 overweight or obese adults (mean BMI 37 kg/m²) with weight‑related comorbidities. The trial evaluated five dose levels against placebo over 42 weeks and met its primary endpoint,...
:max_bytes(150000):strip_icc():format(jpeg)/letrozole-femara-for-fertility-success-rates-safety-1960195-9dcd7e59b80546adb1c468ba927c6711.jpg)
Discover How Letrozole Can Boost Your Fertility Naturally
Letrozole (Femara) is increasingly prescribed to induce ovulation in patients with polycystic ovary syndrome and unexplained infertility, often replacing clomiphene (Clomid) as the preferred first‑line therapy. Clinical studies show letrozole delivers higher ovulation and live‑birth rates while reducing the incidence...
:max_bytes(150000):strip_icc():format(jpeg)/botox-injection-530449582-577168d85f9b585875ba2720.jpg)
What You Need to Know About Botox Use While Breastfeeding
Botox injections are generally deemed safe for nursing parents, though scientific data are scarce. Experts advise breastfeeding before the procedure and waiting several hours afterward to further limit any potential toxin transfer. The treatment’s minimal systemic absorption means the risk...
War in Iran, Healthcare Resurgence & Isa Changes: The Companies and Markets Show
The episode examines the fallout from the US‑Israel strike on Iran, with Mike Ferhey explaining how disruptions to the Strait of Hormuz and attacks on LNG facilities are driving sharp spikes in oil and gas prices, pressuring European energy markets,...
NHS England Urges Patients to Use App Notifications
NHS England launched a “Tap the NHS App” campaign urging patients to enable push notifications for appointment reminders. A Censuswide survey found 12% of respondents forgot appointments and 11% arrived late, amounting to an estimated 16 million missed GP visits in...
Obstructive Vs. Nonobstructive Hypertrophic Cardiomyopathy: Understanding Your Diagnosis
Hypertrophic cardiomyopathy (HCM) is divided into obstructive and nonobstructive forms, each defined by how thickened heart muscle affects blood flow. Both share genetic origins and similar symptoms such as shortness of breath and palpitations, but obstructive HCM creates a dynamic...